Humboldt Fund
Francisco Dopazo is an accomplished professional with extensive experience in investment and management roles. Currently serving as General Partner at Humboldt Fund and Partner at Posterus Partners, Francisco is also a Co-Founder of Khora Therapeutics and Founder of Synkrino Development Company. Francisco's previous positions include Senior Director at Tishman Speyer and Portfolio Director at WeWork, in addition to a Vice President role at J.P. Morgan. Francisco started the career as Caribbean Territory Manager at Latmedical, LLC. Academic credentials include an MBA from the Massachusetts Institute of Technology, an MS in Data Analytics from Columbia University, and a BS in Engineering/Industrial Management from Universidad Metropolitana (VE).
This person is not in any teams
Humboldt Fund
Humboldt Fund is a venture capital fund that supports innovative, early-stage companies by investing in the biotech revolution. Synthetic biology is poised to transform the way we make chemicals, materials, foods and medicines. At Humboldt Fund, they identify and invest in pioneers of engineering, physical sciences and life sciences to bring emerging biotech enterprises to a global market. Together they explore, discover and create new technologies that disrupt global conventions and solve the critical issues of our world, while creating value and prosperity.